valu usd unless otherwis note
 system out-performance highlight
view overal momentum gener surgeri continu
allow compani continu spend acceler develop
work sever pipelin technolog expand
allow compani remain premium player surgic
robot market despit new/upcom competit rais
estim price target move higher
post better expect result report
non-gaap revenu fce upsid driven
fce non-gaap oper margin fce
y/i even y/i increas headcount
non-gaap fce manag maintain
non-gaap gm guidanc fce
better expect system placement driven primarili higher
 trade-in oper leas world-wide system placement
fce system placement fce
intern system placement fce system
ship oper leas vs last quarter trade-in
repres system placement vs
averag system price rbce
system ship xi vs
da vinci system vs
rais bottom-end procedur growth guidanc
fce ww da vinci procedur grew
y/i fce da vinci procedur grew y/i rbce
ou procedur grew y/i rbce dvp
growth in-line growth gyn procedur
strong led solid growth hernia repair colorect bariatr
thorac instrument accessori revenue/procedur
rbce y/i due increas usag advanc
instrument currenc benefit custom buy pattern
continu execut growth strategi pipelin
expand continu view manag procedur growth
gross margin guidanc prudent conserv leav room
potenti upsid strong execut manag chang
oper expens growth guidanc y/i
believ right decis manag continu aggress
reinvest upsid drive intern growth acceler
technolog invest manag receiv question back
fda regard sp continu expect limit launch
da vinci sp separ manag expect file
flexibl cathet system year-end initi build
commerci team platform
price prior trade day market close estimate unless otherwis note
bloomberg capit market estim upside/downside/target
base scenario assum share rise
share base weight intrins valu
calcul dcf analysi
weight intrins valu calcul ev/ebitda
analysi assum continu
increas penetr us gener surgeri
intern surgic market estim
world-wide instal base system da
vinci procedur perform annual includ lung
upsid scenario assum share rise
base dcf model termin valu
ev/ebitda multipl assum continu
increas penetr us gener surgeri
intern surgic market addit assum
acceler upgrad opportun da vinci
success penetr natur orific procedur sp
dollar lung biopsi opportun jv
fosun pharma estim world-wide
instal base system da vinci procedur
perform annual includ lung biopsi
downsid scenario assum share fall
base dcf model termin valu ev/ebitda
multipl also assum ultim penetr
gener surgeri market disappoint da vinci sp
competit robot entri us forc
addit pressur da vinci price estim
world-wide instal base nearli system
da vinci procedur perform annual
includ lung biopsi assum lung biopsi
platform delay
believ share perform line
peer group follow key reason
 da vinci prostatectomi hysterectomi procedur
combin grow low-singl digit y/i
penetr target us prostatectomi
us hysterectomi market robot respect
two procedur compris
total procedur believ issu lead past
slow market well behind
expect market-lik growth dvp dvh
take
gener surgeri market repres main near-
term procedur growth driver recent strong
colorectal/hernia trend appear sustain
urolog gynecolog market combin
time train surgeon
develop opportun isrg gener surgeri
procedur growth focus cholecystectomi
us
howev cholecystectomi flattish four
main growth driver gener surgeri hernia
colorect bariatr thorac recent channel
check robot survey give us confid
real sustain opportun
pictur continu execut growth
strategi gener surgeri intern
pipelin expand remain confid two
import procedur growth driver
colorect hernia sustain
long runway ahead intern market
system front submit
urolog indic expect urolog repres first
fda approv indic sp follow transor
colorect addit earli human clinic
experi prototyp transor catheter-bas
robot platform initi use lung biopsi
add yet anoth outer-year growth opportun
addit analytics/imag opportun
next-gener system develop
upcom catalyst event
commerci da vinci sp commerci
lung biopsi system
commerci risk fda regulatori risk
competit risk legal risk reimburs risk
perform dcf ev/ebitda analysi arriv intrins valu
share dcf analysi use wacc assum termin valu ev/ebitda
multipl base dcf analysi estim intrins valu
approxim separ conduct ev/ebitda analysi use publicli
trade med-tech compar compani analysi point averag forward ev/
ebitda multipl large-cap med-tech compani super premium large-cap
med-tech diagnost compani assign target non-gaap ebitda
multipl premium peer group owe expect
superior top-lin growth rel peer given isrg above-averag oper
margin multipl equat intrins valu deriv price target
assign weight intrins valu calcul dcf analysi
weight intrins valu calcul ev/ebitda analysi
price target impli return support sector perform rate
risk rate price target
face risk typic medic devic compani risk price target
rate includ slower-than-expect gener surgeri procedur growth one
lead indic futur system placement slower-than-expect system ramp da
vinci xi sp lung biopsi procedur declin two three core
market hysterectomi prostatectomi competit risk titan
medic expect gain fda/eu approv robot system
time frame potenti neg public futur clinic studi surgic societi
advers event on-going lawsuit fda regulatori risk surround new robot
platform devic reimburs risk risk
found current market leader world-wide robot market
compani went public receiv fda approv two key indic
benign prostatectomi hysterectomi focus five key surgic
specialti urolog surgeri gynecolog surgeri gener surgeri cardiothorac surgeri
head neck surgeri urolog gynecolog procedur repres around two-
third total world-wide procedur perform da vinci system incorpor
delawar corpor headquart locat sunnyval california compani
manufactur da vinci system facil sunnyval california instrument
made sunnyval facil mexicali mexico facil
amort intang
